Pages that link to "Q42671287"
Jump to navigation
Jump to search
The following pages link to Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials (Q42671287):
Displaying 50 items.
- BTS Guidelines for the Management of Community Acquired Pneumonia in Adults (Q24675547) (← links)
- A critical review of the fluoroquinolones: focus on respiratory infections (Q28215446) (← links)
- Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756 (Q28344944) (← links)
- A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design (Q28476705) (← links)
- Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint (Q30620954) (← links)
- In vitro susceptibilities of Bartonella and Rickettsia spp. to fluoroquinolone antibiotics as determined by immunofluorescent antibody analysis of infected Vero cell monolayers (Q30713575) (← links)
- Gatifloxacin, an advanced 8-methoxy fluoroquinolone (Q31975922) (← links)
- Expanded activity and utility of the new fluoroquinolones: a review (Q33544588) (← links)
- Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus (Q33555316) (← links)
- What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections? (Q33684237) (← links)
- Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. (Q33695250) (← links)
- Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review (Q33739099) (← links)
- New concepts in antimicrobial therapy for emergency department infections (Q33758341) (← links)
- Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections (Q33767602) (← links)
- Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi (Q33769931) (← links)
- Pharmacokinetics and pharmacodynamics of fluoroquinolones (Q33770078) (← links)
- Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology (Q33827819) (← links)
- Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters (Q33895157) (← links)
- Pharmacodynamics of antibacterial drugs (Q33928642) (← links)
- Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics (Q33937527) (← links)
- Ambulatory use of parenteral antibacterials: contemporary perspectives (Q33938974) (← links)
- A clinical pathway for community-acquired pneumonia: an observational cohort study (Q33953008) (← links)
- Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection (Q33976517) (← links)
- Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid (Q33979516) (← links)
- Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species (Q33981082) (← links)
- Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. (Q33981554) (← links)
- Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection (Q33981666) (← links)
- In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model (Q33982034) (← links)
- Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats (Q33982098) (← links)
- Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae (Q33982211) (← links)
- Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. (Q33982552) (← links)
- Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections (Q33983119) (← links)
- Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients (Q33983228) (← links)
- Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time (Q34069810) (← links)
- Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations (Q34077003) (← links)
- Ciprofloxacin dosage and emergence of resistance in human commensal bacteria (Q34104262) (← links)
- Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication (Q34104410) (← links)
- Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus (Q34107094) (← links)
- Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models (Q34108149) (← links)
- Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model (Q34108406) (← links)
- Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection (Q34110906) (← links)
- Pneumococcal resistance: the treatment challenge (Q34219099) (← links)
- Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis (Q34228256) (← links)
- Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model (Q34230600) (← links)
- Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials (Q34235318) (← links)
- A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections (Q34248416) (← links)
- Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions (Q34274190) (← links)
- The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy (Q34289714) (← links)
- In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model (Q34301493) (← links)
- Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. (Q34307105) (← links)